Show simple item record

dc.contributor.authorFrancis, GD
dc.contributor.authorDimech, M
dc.contributor.authorGiles, L
dc.contributor.authorHopkins, A
dc.date.accessioned2017-09-06T00:08:24Z
dc.date.available2017-09-06T00:08:24Z
dc.date.issued2007
dc.date.modified2008-07-07T01:32:13Z
dc.identifier.issn0021-9746
dc.identifier.doi10.1136/jcp.2006.044701
dc.identifier.urihttp://hdl.handle.net/10072/19473
dc.description.abstractBackground and Aims: Immunohistochemistry (IHC) has replaced radioligand binding assay for the determination of oestrogen receptor (ER) status in breast carcinoma. IHC is also used for assessment of progesterone receptor (PR) and HER2. The Royal College of Pathologists of Australasia (RCPA) Quality Assurance Program (QAP) introduced a breast markers module in 2003 to evaluate the performance of laboratories with IHC for ER, PR and HER2. Methods: An audit of laboratories reporting breast carcinomas was performed in 2005 and 2006 to evaluate in-house results. Laboratories were asked to submit the hormone receptor and HER2 status on each invasive breast carcinoma for the previous 6 month period up to a maximum of 100 cases. The time periods were 1 July 2004 to 31 December 2004, and 1 July 2005 to 31 December 2005. A total of 55 laboratories returned information for 2004 and 67 for 2005. Results: Complete data on 8128 patients was returned for both surveys, 3353 cases for 2004 and 4775 for 2005. The results were similar for both surveys. Of the 8128 cases, 59.0% were ER+/PR+, 15.9% ER+/PR−, 2.4% ER−/PR+ and 22.7% ER−/PR−. HER2 data were submitted for a total of 6512 patients (excludes 52 patients with incomplete data sets); 17.1% were reported as 3+ positive on IHC, 12.5% as 2+ and 70.4% as negative. Conclusions: A laboratory audit was introduced into the RCPA QAP for breast markers due to concerns raised by participating laboratories about technical differences in supplied tissues for testing. This audit indicates that overall the results for ER, PR and HER2 fall inside established parameters. However, a number of individual laboratories do not meet the target values and variation in results would impact on patient treatment decisions.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.publisher.placeUK
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1277
dc.relation.ispartofpageto1283
dc.relation.ispartofissue11
dc.relation.ispartofjournalJournal of Clinical Pathology
dc.relation.ispartofvolume60
dc.rights.retentionY
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchMedical Microbiology
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1108
dc.titleFrequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.date.issued2007
gro.hasfulltextNo Full Text
gro.griffith.authorFrancis, Glenn D.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record